Humanigen Inc (HGENQ)

[cowtown jay]

They don't want something that is variant-agnostic. They want variant-specific in order to keep Big Pharma's revenue stream rolling.

Supposedly, the ACTIV-5 results are being drafted, with a Q1 or Q2 target date for the Final Report and Conclusions.

And by the way, in terms of the second drug patent, the patient would not be administered lenz if he didn't have covid...or had just contracted covid from the vaccine, which would effectuate the immune response that lenz would then target. But that would still represent the use of lenz where there was no natural cause for the disease.

That's why I think using lenz as a postexposure prophylaxis (PEP) is an absolutely brilliant solution. If patients contract covid naturally, lenz would be used as intended in the trials. But gaining access to postexposure patients is just a step down from being a vaccine, and we will trash a significant portion of the vaccine market, except for the vaccine used with lenz.